Soufflé Therapeutics

Soufflé Therapeutics is a biotechnology company founded in 2022 that develops targeted, tissue-specific genetic therapies. The firm's platform discovers new cell proteins and pathways to deliver genetic payloads, specifically small interfering RNA (siRNA) medicines, to designated cells. This approach enables the treatment of various autoimmune and cardiac diseases by targeting macrophages and cardiac cells. The company's initial programs focus on facioscapulohumeral muscular dystrophy (FSHD) and cardiomyopathies caused by mutations in the phospholamban (PLN) gene, with clinical trials anticipated to start in 2026.

The company was co-founded by a team of prominent figures in genetic medicine, including Robert Langer (co-founder of Moderna), Daniel Anderson, and Victor Kotelianski, who previously served as the founding SVP of research at Alnylam. The leadership team includes CEO Amir Nashat, a former Managing Partner at Polaris Partners, and Founding President and Chief Business Officer Susan Langer, who has held leadership roles at Biogen, Paratus Sciences, and Kojin Therapeutics. The company operates on a business model that involves collaborations with pharmaceutical companies and strategic venture capital investors. Soufflé has secured significant capital through these partnerships and funding rounds. As a privately held, venture-capital-backed entity, the company has raised funds from investors such as Vida Ventures, ARCH Venture Partners, Polaris Partners, Safar Partners, and Bessemer Venture Partners.

Keywords: genetic medicine, siRNA therapeutics, targeted drug delivery, gene therapy, autoimmune diseases, cardiac diseases, FSHD, PLN gene mutation, cardiomyocyte targeting, macrophage targeting, Robert Langer, Amir Nashat, Susan Langer, Victor Kotelianski, Polaris Partners, ARCH Venture Partners, Vida Ventures, biotechnology, pharmaceutical research, genetic payloads